About: Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines
Creator	Aurer, Igor Federico, Massimo Zing, Natalia
Source	PMC
abstract	covid:fe30a7d8fdc2cadb02ee30e5b12075377506fae6#abstract
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1097/hs9.0000000000000458
has license	cc-by-nc-nd
sha1sum (hex)	fe30a7d8fdc2cadb02ee30e5b12075377506fae6
schema:url	https://doi.org/10.1097/hs9.0000000000000458
resource representing a document's title	Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines
has PubMed Central identifier	PMC7375184
schema:publication	Hemasphere
resource representing a document's body	covid:fe30a7d8fdc2cadb02ee30e5b12075377506fae6#body_text
is schema:about of	named entity 'Clinical Practice Guidelines' named entity 'Hodgkin Lymphoma' named entity 'standard of care' named entity 'cyclophosphamide' named entity 'ABVD' named entity 'radiation therapy' named entity 'toxicity' named entity 'Clinical Practice Guidelines' named entity 'autologous stem cell transplantation' named entity 'refractory' named entity 'ASCT' named entity 'adriamycin' named entity 'G-CSF' named entity 'lung' named entity 'chemotherapy' named entity 'ABVD' named entity 'chemotherapy' named entity 'toxicity' named entity 'LyG' named entity 'ASCT' named entity 'EORTC' named entity 'PET' named entity 'chemotherapy' named entity 'PET' named entity 'doxorubicin' named entity 'etoposide' named entity 'procarbazine' named entity 'bleomycin' named entity 'prognostic' named entity 'dacarbazine' named entity 'Adriamycin' named entity 'follow-up' named entity 'United States' named entity '5-year survival' named entity 'risk group' named entity 'prednisone' named entity 'Clinical Practice Guidelines' named entity 'Oncovin' named entity 'hematological malignancies' named entity 'brentuximab vedotin' named entity 'phase 2' named entity 'antibodies' named entity 'Hodgkin lymphoma' named entity 'vinblastine' named entity 'bleomycin' named entity 'bleomycin' named entity 'PET' named entity 'Comments' named entity 'Guidelines' named entity 'ESMO' named entity 'Hodgkin Lymphoma' named entity 'CLINICAL PRACTICE GUIDELINES' named entity 'COMMENTS' named entity 'HODGKIN LYMPHOMA'
is part of of	covid:fe30a7d8fdc2cadb02ee30e5b12075377506fae6#body_text Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines covid:fe30a7d8fdc2cadb02ee30e5b12075377506fae6#abstract

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software